Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 677 News
1 - 10of about 677 News
May 23, 2022
Not intended for U.S. and UK Media - Late-breaking data from exploratory post hoc analysis of prespecified pooled analysis FIDELITY presented at Heart Failure 2022 of the Heart Failure Association of the European Society of Cardiology (ESC)
New data support renal and cardiovascular benefits of Kerendia™ (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes
READ MORE
May 19, 2022
Not intended for U.S. and UK Media
Verquvo™ (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction
READ MORE
May 10, 2022
First quarter at Bayer:
Very good start to the year – strong sales and earnings growth
READ MORE
May 03, 2022
Not intended for U.S. and UK Media
U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)
READ MORE
April 29, 2022
CEO Werner Baumann at the Annual Stockholders’ Meeting:
“Bayer is on the right track”
READ MORE
April 22, 2022
Not intended for U.S. and UK Media
Bayer submits application in China for additional indication of darolutamide
READ MORE
April 13, 2022
Not intended for U.S. and UK Media
Bayer receives approval for precision oncology treatment Vitrakvi™ in China
READ MORE
April 03, 2022
Not intended for U.S. and UK Media – American College of Cardiology’s 71st Annual Scientific Session (ACC.22):
Bayer presents positive results from first Phase 2b trial on safety of asundexian in patients with atrial fibrillation
READ MORE
April 01, 2022
Breakthrough Innovation Forum
Bayer set to drive breakthrough innovations in the Life Sciences
READ MORE
March 28, 2022
Not intended for U.S. and UK Media
Bayer receives approval in Japan for Kerendia™ (finerenone), a new treatment for adults with chronic kidney disease and type 2 diabetes
READ MORE
1 - 10of about 677 News
1 - 10of about 677 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more